ABIRASTERON 250- Steris Healthcare PVT LTD

ABIRASTERON 250

Abiraterone Acetate lp (250mg)

ABIRASTERON 250 contains Abiraterone Acetate LP at a concentration of 250mg, offering a targeted approach to treating advanced prostate cancer. This medication is specifically designed to inhibit androgen production, slowing cancer progression and improving outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC). Let's explore the features, benefits, and usage guidelines for ABIRASTERON 250 in prostate cancer therapy.

Key Features and Benefits

• Androgen Deprivation Therapy: Abiraterone Acetate LP in ABIRASTERON 250 inhibits the enzyme CYP17, crucial for androgen synthesis in prostate cancer cells, leading to reduced testosterone levels and tumor shrinkage.
• Effective in mCRPC: ABIRASTERON 250 is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) that has progressed on prior hormone therapy.
• Prolongs Survival: By targeting androgen production pathways, ABIRASTERON 250 can prolong overall survival and delay disease progression in patients with advanced prostate cancer.

Indications for Use

ABIRASTERON 250 is indicated for the treatment of:

• Metastatic Castration-Resistant Prostate Cancer (mCRPC): In combination with prednisone or prednisolone, ABIRASTERON 250 is used for the treatment of mCRPC in patients who have received prior androgen deprivation therapy (ADT) and progressed on it.

Dosage and Administration

The recommended dosage of ABIRASTERON 250 (Abiraterone Acetate LP 250mg) may vary based on individual patient factors and treatment response. It is typically taken orally once daily, preferably on an empty stomach at least one hour before or two hours after a meal. The medication is usually administered in combination with low-dose corticosteroids such as prednisone or prednisolone to reduce potential side effects.

Conclusion

ABIRASTERON 250 (Abiraterone Acetate LP 250mg) is a valuable therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC), offering targeted and effective androgen deprivation therapy. With its proven efficacy and manageable side effect profile, ABIRASTERON 250 plays a crucial role in improving outcomes and quality of life for patients with advanced prostate cancer. Steris Healthcare Pvt Ltd, founded by a group of expert professionals in the pharmaceutical industry in February 2018, operates as Sterispharma. This company, which is based in Navi Mumbai, holds certifications from WHO, GMP, and ISO. Its commitment is to provide high-quality drugs at affordable prices to its customers throughout India, following the rigorous guidelines set by the WHO. Steris offers the convenience of an online pharmacy where customers can easily buy medicines and enjoy the benefit of home delivery. At Steris, the mission is to supply a wide array of healthcare products designed to meet the varied needs of the medical community. Whether it is advanced treatments, medications for rare conditions, or basic health necessities, Sterispharma strives to serve the healthcare industry’s broad demands. The extensive product lineup from Steris includes treatments for various health areas such as Cardiology, Asthma, Respiratory issues, Nasal conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental care, and Dermatology.

 For further information: 

 EMAIL:  info@sterispharma.com  / contact@sterispharma.com   

 CALL/WHATSAPP: 7877551268, 7849827488

 BUY NOW